CorMedix
CRMD
59 hedge funds and large institutions have $23.7M invested in CorMedix in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 9 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
0.21% more ownership
Funds ownership: 25.11% → 25.32% (+0.21%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 62 → 59 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
49% less capital invested
Capital invested by funds: $46.9M → $23.7M (-$23.1M)
88% less call options, than puts
Call options by funds: $78K | Put options by funds: $638K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$413K |
| 2 |
Renaissance Technologies
New York
|
+$410K |
| 3 |
OFG
Oxford Financial Group
Carmel,
Indiana
|
+$317K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$266K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$238K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PD
Planning Directions
Glen Mills,
Pennsylvania
|
-$364K |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$258K |
| 3 |
D.E. Shaw & Co
New York
|
-$221K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$201K |
| 5 |
Morgan Stanley
New York
|
-$198K |
CRMD Hedge Fund Activity: Q1 2020 in Review
59 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2020, worth a combined $23.7M — down 49% from $46.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CRMD and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 21 added.
The largest buyer was Vanguard Group, adding an estimated $413K. The largest seller was Planning Directions, exiting entirely with an estimated $364K sold.
- 59 institutional investors held CorMedix (CRMD) as of Q1 2020, down from 62 in Q4 2019.
- Funds reported $23.7M of CorMedix stock for Q1 2020, down 49% quarter-over-quarter.
- 7 funds opened new CorMedix positions in Q1 2020 and 9 closed out, a net change of -2 holders.
- The largest CorMedix buyer in Q1 2020 was Vanguard Group, an estimated $413K added.
- The largest CorMedix seller in Q1 2020 was Planning Directions, an estimated $364K sold.
Based on aggregated 13F filings for Q1 2020.